Castle Biosciences, Inc. - CSTL STOCK NEWS

Castle Biosciences (Nasdaq: CSTL), a company specializing in innovative health tests for patient care, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's executive management is scheduled to present a company overview on Tuesday, Aug. 13, 2024, at 12:30 p.m. Eastern time.

Investors and interested parties can access a live audio webcast of the presentation through Castle Biosciences' website at ir.castlebiosciences.com/events-presentations/. For those unable to attend the live event, a replay of the webcast will be made available after the presentation concludes.

Castle Biosciences (Nasdaq: CSTL) has partnered with Teddi Mellencamp Arroyave, a stage II melanoma survivor, to launch a campaign raising awareness about melanoma prevention, detection, and management. Mellencamp Arroyave will share her personal journey with melanoma on Instagram, alongside discussions with Dr. Aaron S. Farberg and melanoma survivor Morgan England.

The campaign aims to educate the public about melanoma, the deadliest form of skin cancer, which claims nearly 20 American lives daily. Castle's DecisionDx®-Melanoma test provides personalized information about a patient's risk of melanoma recurrence, metastasis, and sentinel lymph node positivity, helping guide treatment decisions and improve patient survival.

Castle Biosciences (Nasdaq: CSTL) has announced the release of its financial results for Q2 and H1 2024 on Monday, Aug. 5, 2024, after market close. The company, which specializes in innovative health tests for patient care, will host a conference call and webcast at 4:30 p.m. Eastern time on the same day to discuss the results.

Investors can access the live webcast through the provided link or via the company's Investor Relations page. For those joining by phone, the U.S. dial-in number is 1 833 470 1428, with international numbers available. The access code for both is 802518. A Q&A session will follow management's commentary, and a replay of the webcast will be available after the call.

Castle Biosciences (Nasdaq: CSTL) has been recognized with several prestigious awards through the 2024 Top Workplaces program. The company earned its third consecutive Arizona Top Workplaces award from AZ Central, a second consecutive national Healthcare Industry Top Workplace award, and five Top Workplaces Culture Excellence Awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership, and Purpose & Values. These accolades are based on anonymous employee feedback collected via a third-party survey by Energage, emphasizing Castle's commitment to a positive workplace culture.

CEO Derek Maetzold expressed pride in the repeated recognition, attributing it to the company's dedication to fostering an exceptional, people-first environment that promotes employee growth and patient care. The Top Workplaces program, now in its 17th year, evaluates companies based on 15 culture drivers, including alignment, execution, and connection.

Castle Biosciences announced that the American Gastroenterological Association (AGA) clinical practice guideline has recognized the importance of tissue-based biomarkers, particularly Castle's TissueCypher® test, in identifying patients with non-dysplastic Barrett’s esophagus (NDBE) who may be at high risk of progressing to esophageal cancer. TissueCypher has been shown to improve risk stratification, helping to identify those who may benefit from early endoscopic eradication therapy (EET). Studies indicate that patients with high-risk scores from the TissueCypher test are 18 times more likely to progress to esophageal cancer compared to those with low-risk scores. This acknowledgment underscores the potential of advanced tissue-based diagnostics in enhancing patient care and preventing cancer progression.

Castle Biosciences (Nasdaq: CSTL) announced that on June 14, 2024, its Compensation Committee granted restricted stock units (RSUs) to 94 employees as an inducement for joining the company. The RSUs cover a total of 158,197 shares of common stock and were issued under the company's 2022 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4). The units will vest over four years, with 25% vesting on the first anniversary of the vesting start date and the remaining shares vesting annually in three equal parts, contingent on the employee's continued service.

Castle Biosciences has announced that its founder, president, and CEO, Derek Maetzold, has been named an EY Entrepreneur Of The Year® 2024 Gulf South Award winner. The award recognizes Maetzold’s impactful leadership and the company’s innovative healthcare solutions since its inception in 2008. The selection was made by an independent panel that evaluated candidates on their entrepreneurial spirit, long-term value creation, and substantial business impact. Castle Biosciences has grown to over 690 employees and generated approximately $220 million in revenue in 2023. Maetzold is now eligible for the national awards, with winners to be announced in November and potentially competing for the World Entrepreneur Of The Year Award in June 2025.

Castle Biosciences will present new data on their DecisionDx-Melanoma and DecisionDx-UM tests at the 2024 ASCO Annual Meeting in Chicago from May 31 to June 4, 2024. The DecisionDx-Melanoma test identifies early-stage melanoma patients at higher risk of CNS metastasis, potentially benefiting from more frequent imaging surveillance. The study showed patients with the highest risk (Class 2B) had higher CNS metastasis rates and lower five-year recurrence-free survival. The DecisionDx-UM test, part of a multi-center study, proved more effective than PRAME and DNA mutation status in predicting metastatic outcomes for uveal melanoma.

Castle Biosciences announced a publication demonstrating the efficacy of their DecisionDx-SCC test in identifying high-risk cutaneous squamous cell carcinoma (SCC) patients who benefit from adjuvant radiation therapy (ART). The study, published in the International Journal of Radiation Oncology • Biology • Physics, revealed that patients with Class 2B test results, indicating the highest risk of metastasis, showed a 50% higher metastasis-free survival (MFS) rate when treated with ART compared to those who did not receive ART. Additionally, Class 1 patients, with lower metastatic risk, did not show improved survival with ART, suggesting they can potentially avoid the treatment.

These findings highlight the test's role in guiding clinical decisions regarding ART, thereby optimizing patient care by balancing treatment benefits against side effects.